The monoclonal anti-TGF-β antibody ascrinvacumab also showed hopeful results among HCC patients in a phase I-II trial (264) and its combinational application with nivolumab is currently under investigation (NCT05178043). Here, TGFB1 is linked to hepatocellular carcinoma.